Noradrenaline Kabi (Noradrenaline Tartrate)

Noradrenaline Kabi is a vasopressor used in critical care to manage life‑threatening circulatory failure.

• Hypotension: restores arterial pressure by increasing systemic vascular resistance in patients with acute low blood pressure.
• Septic shock: counteracts vasodilatory shock by raising mean arterial pressure to improve organ perfusion.
• Cardiac arrest: provides immediate vasoconstrictive support during resuscitation to maintain coronary and cerebral perfusion.

• Norepinephrine acts as a direct agonist at alpha‑1 adrenergic receptors on vascular smooth muscle, producing vasoconstriction and increasing systemic vascular resistance. It also stimulates beta‑1 receptors in the heart, modestly enhancing cardiac contractility and heart rate. The combined alpha‑mediated vasoconstriction and beta‑mediated inotropic effect elevate mean arterial pressure, supporting perfusion in shock states. The net effect is a rapid rise in blood pressure without significant change in pulmonary vascular resistance.

Norepinephrine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild to moderate headache may occur.
• Tremor: transient shaking of hands or limbs.
• Nausea: occasional nausea or vomiting.
• Palpitations: sensation of rapid or irregular heartbeat.
• Anxiety: feeling of nervousness or restlessness.
• Sweating: increased perspiration.

Serious or Rare Side Effects

• Severe hypertension: excessive rise in blood pressure leading to vascular injury.
• Cardiac arrhythmia: potentially life‑threatening irregular heart rhythms.
• Peripheral ischemia: reduced blood flow to extremities causing pain or necrosis.
• Lactate accumulation: metabolic acidosis risk.
• Extravasation injury: tissue damage if solution leaks from vein.

Use of Noradrenaline Kabi requires careful monitoring and adherence to safety guidelines.

• Hemodynamic monitoring: continuously assess blood pressure and heart rate during infusion.
• Dose titration: adjust infusion rate to achieve target mean arterial pressure.
• Electrolyte balance: monitor serum potassium and calcium levels, correcting abnormalities.
• Contraindications: avoid use in patients with uncorrected hypovolemia or pheochromocytoma.
• Drug compatibility: administer through dedicated line; avoid mixing with solutions that may precipitate.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Norepinephrine can interact with several agents, influencing its efficacy or safety.

Major Interactions (Avoid)

• Beta‑blockers: may blunt the chronotropic response, reducing heart rate increase.
• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis due to excess catecholamines.
• Tricyclic antidepressants: additive vasoconstriction may cause severe hypertension.

Moderate Interactions (Monitor Closely)

• Vasodilators (e.g., nitroglycerin): may counteract norepinephrine’s pressor effect, requiring higher doses.
• Calcium channel blockers: can enhance negative inotropic effects, necessitating cardiac monitoring.
• Diuretics: volume depletion may potentiate hypotensive episodes if norepinephrine is tapered.